Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
NCT02467270
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
283
Enrollment
INDUSTRY
Sponsor class
Conditions
Myeloid Leukemia, Chronic, Chronic Phase
Interventions
DRUG:
Ponatinib
Sponsor
Takeda